BeiGene Ties Up With Novartis To Take PD-1 Global In $2.2bn+ Deal
Bets on China Data, Differentiation Strategy
BeiGene has teamed up with Novartis to take its PD-1 antibody global after an earlier major deal with Celgene was terminated following the BMS acquisition, and amid intense market and pricing competition in the immuno-oncology sector in China.
